Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
File version
Author(s)
Elms, Jackson
Munn, Alan L
Good, David
Wei, Ming Q
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Non-small cell lung cancer (NSCLC) is of major concern for society as it is associated with high mortality and is one of the most commonly occurring of all cancers. Due to the number of mutational variants and general heterogeneity of this type of cancer, treatment using conventional modalities has been challenging. Therefore, it is important to have improved therapeutic treatments like immunotherapy, that can specifically treat the disease while causing minimal damage to healthy tissue and additionally provide systemic immunity. Cancer vaccines are an important element of cancer immunotherapy and have been approved for treatment of a limited number of cancers, including NSCLC. This article highlights scientific evidence for several therapeutic treatment strategies for NSCLC, alone or in combination, which offers new hope for those suffering. Although cancer vaccines have had some success as a monotherapy, their potential in a combination therapy needs to be critically analyzed for future applications.
Journal Title
Critical Reviews in Oncology/Hematology
Conference Title
Book Title
Edition
Volume
164
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Cardiovascular medicine and haematology
Oncology and carcinogenesis
Cancer vaccines
Checkpoint inhibitors
Combination therapy
Conventional treatments
Immunotherapy
Persistent link to this record
Citation
Kaur, J; Elms, J; Munn, AL; Good, D; Wei, MQ, Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy, Critical Reviews in Oncology/Hematology, 2021, 164, pp. 103417